Guggenheim lowered the firm’s price target on Ultragenyx (RARE) to $52 from $64 and keeps a Buy rating on the shares after the company announced the failure of the ORBIT and COSMIC studies evaluating setrusumab in osteogenesis imperfecta.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE: